Evidence map›Paper›PMID 37828150›Full record

ArticleCommunications biology2023

Rare antibody phage isolation and discrimination (RAPID) biopanning enables identification of high-affinity antibodies against challenging targets.

Dong Hee Chung, Sophie Kong, Nicholas J Young, Shih-Wei Chuo, Jamie V Shiah, Emily J Connelly, Peter J Rohweder, Alexandra Born, Aashish Manglik, Jennifer R Grandis and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Dong Hee ChungDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, 94158, USA.
Sophie KongDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, 94158, USA.
Nicholas J YoungDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, 94158, USA.
Shih-Wei ChuoDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, 94158, USA.
Jamie V ShiahDepartment of Otolaryngology - Head and Neck Surgery, University of California San Francisco, San Francisco, CA, 94158, USA.
Emily J ConnellyThe Pharmaceutical Sciences and Pharmacogenomics Graduate Program, University of California San Francisco, San Francisco, CA, 94158, USA.ORCID http://orcid.org/0000-0003-0732-1627
Peter J RohwederDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, 94158, USA.
Alexandra BornDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, 94158, USA.ORCID http://orcid.org/0000-0001-8258-0982
Aashish ManglikDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, 94158, USA.ORCID http://orcid.org/0000-0002-7173-3741
Jennifer R GrandisDepartment of Otolaryngology - Head and Neck Surgery, University of California San Francisco, San Francisco, CA, 94158, USA.
Daniel E JohnsonDepartment of Otolaryngology - Head and Neck Surgery, University of California San Francisco, San Francisco, CA, 94158, USA.
Charles S CraikDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, 94158, USA. charles.craik@ucsf.edu.ORCID http://orcid.org/0000-0001-7704-9185
University of California, San Francisco · US

Funding

Project 3U54AI170792 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Nevan J Krogan · 2022 to 2026
$35.7M
Molecular and Cellular Mechanisms in CancerT32CA108462 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOGA, ANDREI · 2004 to 2024
$10.4M
Targeting STAT3 to enhance anti-tumor immunityR01DE028289 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN, JOHNSON, DANIEL E · 2019 to 2023
$3.2M
Research Training in Chemistry and Chemical BiologyT32GM145460 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jason E Gestwicki · 2022 to 2026
$3.1M
Probing the Role of Chaperone-TPR Complexes in Tau ProteostasisRF1AG068125 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRAIK, CHARLES SCOTT, GESTWICKI, JASON E · 2020 to 2020
$2.2M
Probing the Role of Chaperone-TPR Complexes in Tau ProteostasisR01AG068125 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRAIK, CHARLES SCOTT, GESTWICKI, JASON E · 2024 to 2024
$569k
NCI NIH HHS T32 CA108462NIAID NIH HHS U54 AI170792NIA NIH HHS R01 AG068125NIA NIH HHS RF1 AG068125NIDCR NIH HHS R01 DE028289NIGMS NIH HHS T32 GM145460
6 · The paper itself

Abstract

In vitro biopanning platforms using synthetic phage display antibody libraries have enabled the identification of antibodies against antigens that were once thought to be beyond the scope of immunization. Applying these methods against challenging targets remains a critical challenge. Here, we present a new biopanning pipeline, RAPID (Rare Antibody Phage Isolation and Discrimination), for the identification of rare high-affinity antibodies against challenging targets. RAPID biopanning uses fluorescent labeled phage displayed fragment antigen-binding (Fab) antibody libraries for the isolation of high-affinity binders with fluorescent activated sorting. Subsequently, discriminatory hit screening is performed with a biolayer interferometry (BLI) method, BIAS (Biolayer Interferometry Antibody Screen), where candidate binders are ranked and prioritized according to their estimated kinetic off rates. Previously reported antibodies were used to develop the methodology, and the RAPID biopanning pipeline was applied to three challenging targets (CHIP, Gαq, and CS3D), enabling the identification of high-affinity antibodies.

Indexed as

BacteriophagesPeptide LibraryAntibodiesAntigensBioprospectingAntibodiesAntigensPeptide Library

Identifiers

PMID37828150
PMCPMC10570357
OpenAlexW4387568476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.